[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]
ICRP-30 and 10 CFR 20
The regulations (10 CFR 20 for NRC and 10 CFR 835 for DOE) do not
specify biokinetic models or dose conversion factors for internal dose
assessment. Obviously some such models had to be used to derive the
DAC and ALI values contained in the appendices to the regulations,
thus use of those DAC and ALI values for any regulation-derived dose
conversion factor implies a default acceptance by the licensee of
whatever model was used to derive the DACs and ALIs.
Regulatory Guide 8.34 does identify ICRP-30 dose conversion factors as
acceptable for factors for compliance calculations. This is a de
facto endorsement of the ICRP-30 models. However, remember that
regulatory guides are not mandatory. The same guide also permits use
of individual or material-specific information.
There is nothing that prevents use of other models for the biokinetics
associated with internal dosimetry. It's ok to use the new ICRP-67
models, the ICRP-66 lung model, and whatever excretion or retention
model you believe you can justify.
What prevents blanket adoption of the newer ICRP approach is that the
regulation very clearly specifies what organ/tissue weighting factors
are to be used - and these are clearly the ICRP-26/30 weighting
factors. Without a change to the regulations, one may not use the new
ICRP-60 weighting factors for compliance dosimetry. Of course,
nothing prevents you from calculating using both systems.
Our European Union friends recently approved a directive to adopt the
ICRP-60 recommendations and have them incorporated into national
legislation by the year 2000. Given how long it took for the United
States to revise 10 CFR 20 to address ICRP-26 concepts, I suspect 2005
or 2010 is a more likely date for the US! But then, I'm an optimist.
Gene Carbaugh
Internal Dosimetry
Pacific Northwest National Laboratory
eh_carbaugh@pnl.gov